[1]
Kreimerman, I.; Porcal, W.; Oliver, P.; Savio, E.; Engler, H. Synthesis of [18F] 2B-SRF101: A sulfonamide derivative of the fluorescent dye sulforhodamine 101. Curr. Radiopharm., 2017, 10(3), 212-220.
[2]
Nimmerjahn, A.; Kirchhoff, F.; Kerr, J.N.D.; Helmchen, F. Sulforhodamine 101 as a Specific Marker of Astroglia in the Neocortex in vivo. Nat. Methods, 2004, 1(1), 31-37.
[3]
Nimmerjahn, A. Helmchen vivo labeling of cortical astrocytes with sulforhodamine 101 (SR101). Cold Spring Harb. Protoc., 2012, 7(3), 326-334.
[4]
Wasseff, S.K.; Scherer, S.S. Cx32 and Cx47 mediate oligodendrocyte: astrocyte and oligodendrocyte: Oligodendrocyte gap junction coupling. Neurobiol. Dis., 2011, 42(3), 506-513.
[5]
Hill, R.A.; Grutzendler, J. In vivo Imaging of Oligodendrocytes with Sulforhodamine 101. Nat. Methods, 2014, 11(11), 1081-1082.
[6]
Hagos, L.; Hülsmann, S. Unspecific labelling of oligodendrocytes by sulforhodamine 101 depends on astrocytic uptake via the thyroid hormone transporter OATP1C1 (SLCO1C1). Neurosci. Lett., 2016, 631, 13-18.
[7]
Hülsmann, S.; Hagos, L.; Heuer, H.; Schnell, C. Limitations of sulforhodamine 101 for brain imaging. Front. Cell. Neurosci., 2017, 11, 1-6.
[8]
Verkhratsky, A.; Olabarria, M.; Noristani, H.N.; Yeh, C.Y.; Rodriguez, J.J. Astrocytes in alzheimer’s disease. Neurotherapeutics, 2010, 7(4), 399-412.
[9]
Kreimerman, I.; Reyes, A.L.; Buccino, P.; Porcal, W.; Oliver, P.; Savio, E.; Engler, H. 18F-Sulforhodamine 101 derivative as a potential agent for astrocytosis diagnosis: Labelling and preliminary biological studies. J. Nucl. Med., 2016, 5(2), 2701a.
[10]
Kranz, M.; Sattler, B.; Tiepolt, S.; Wilke, S.; Deuther-Conrad, W.; Donat, C.K.; Fischer, S.; Patt, M.; Schildan, A.; Patt, J.; Smits, R.; Hoepping, A.; Steinbach, J.; Sabri, O.; Brust, P. Radiation dosimetry of the alpha4beta2 nicotinic receptor ligand (+)-[18f]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results. EJNMMI Phys., 2016, 3(1), 1-17.
[11]
Karimi, M.; Tu, Z.; Yue, X.; Zhang, X.; Jin, H.; Perlmutter, J.S.; Laforest, R. Radiation dosimetry of [18F]VAT in nonhuman primates. EJNMMI Res., 2015, 5(1), 1-6.
[12]
Marti-Climent, J.M.; Collantes, M.; Jauregui-Osoro, M.; Quincoces, G.; Prieto, E.; Bilbao, I.; Ecay, M.; Richter, J.A.; Peñuelas, I. Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide pet ligand [18F]-tetrafluoroborate. EJNMMI Res., 2015, 5(1), 1-9.
[13]
Waterhouse, R.N.; Zhao, J.; Stabin, M.G.; Ng, H.; Schindler-Horvat, J.; Chang, R.C.; Mirsalis, J.C. Preclinical acute toxicity studies and dosimetry estimates of the novel sigma-1 receptor radiotracer, [18F]SFE. Mol. Imaging Biol., 2006, 8(5), 284-291.
[14]
M3(R2); ICH, E. ICH M3(R2) - Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Int. Conf. Harmon., 2009, pp. 1-25.
[15]
Koziorowski, J.; Behe, M.; Decristoforo, C.; Ballinger, J.; Elsinga, P.; Ferrari, V.; Kolenc Peitl, P.; Todde, S.; Mindt, T.L. Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals. EJNMMI Radiopharm. Chem., 2017, 1(1), 1-6.
[16]
Nair, A.B.; Jacob, S. A Simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm., 2016, 7(2), 27-31.
[17]
Eckerman, K.; Endo, A. MIRDRadionuclide data and decay schemes 2nd Edn (Reston; VA: Society for nuclear medicine), 2008.
[18]
Salabert, A-S.; Mora-Ramirez, E.; Beaurain, M.; Alonso, M.; Fontan, C.; Tahar, H.B.; Boizeau, M.L.; Tafani, M.; Bardiès, M.; Payoux, P. Evaluation of [18F] FNM biodistribution and dosimetry based on whole-body PET imaging of rats. Nucl. Med. Biol., 2018, 59, 1-8.
[19]
Mathematica ,Version 10.4; Version 10.4; Champaign, Illinois, 2015.
[20]
McParland, B.J. Nuclear Medicine Radiation Dosimetry: Advanced Theoretical Principles; Springer Science & Business Media, 2010.
[21]
Stabin, M.G.; Sparks, R.B.; Crowe, E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med., 2005, 46(6), 1023-1027.
[22]
Stabin, M.; Siegel, J.A. Radar dose estimate report: A compendium of radiopharmaceutical dose estimates based on Olinda/Exm Version 2.0. J. Nucl. Med., 2018, 59(1), 154-160.
[23]
Stabin, M.G.; Xu, X.G.; Emmons, M.A.; Segars, W.P.; Shi, C.; Fernald, M.J. RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. J. Nucl. Med., 2012, 53, 1807-1813.
[24]
ICRP Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. A Report of Age- and Gender-Related Differences in the Anatomical and Physiological Characteristics of Reference Individuals. ICRP Publication 89. Ann. ICRP, 2002, 32(3-4), 5-265.
[25]
Protection, R. ICRP Publication 103. Ann. ICRP, 2007, 37(2.4), 2.
[26]
Guerriero, F.; Ferrari, M.E.; Botta, F.; Fioroni, F.; Grassi, E.; Versari, A.; Sarnelli, A.; Pacilio, M.; Amato, E.; Strigari, L.; Bodei, L.; Paganelli, G.; Iori, M.; Pedroli, G.; Cremonesi, M. kidney dosimetry in 177lu and 90y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res. Int., 2013, 1-12.
[27]
Boschi, S.; Lee, J.T.; Beykan, S.; Slavik, R.; Wei, L.; Spick, C.; Eberlein, U.; Buck, A.K.; Lodi, F.; Cicoria, G.; Czernin, J.; Lassmann, M.; Fanti, S.; Herrmann, K. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(12), 2122-2130.
[28]
Kranz, M.; Sattler, B.; Wüst, N.; Deuther-Conrad, W.; Patt, M.; Meyer, P.M.; Fischer, S.; Donat, C.K.; Wünsch, B.; Hesse, S.; Steinbach, J.; Brust, P.; Sabri, O. Evaluation of the enantiomer specific biokinetics and radiation doses of [18 F] fluspidine-a new tracer in clinical translation for imaging of Σ1receptors. Molecules, 2016, 2(9), 1164-1178.
[29]
Waterhouse, R.N.; Stabin, M.G.; Page, J.G. Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [18 F] FPS. Nucl. Med. Biol., 2003, 30, 555-563.
[30]
Beykan, S.; Dam, J.S.; Eberlein, U.; Kaufmann, J.; Kjærgaard, B.; Jødal, L.; Bouterfa, H.; Lassmann, M.; Jensen, S.B. [177Lu]-OPS201 targeting somatostatin receptors: In vivo biodistribution and dosimetry in a pig model. Eur. J. Nucl. Med. Mol. Imaging, 2016, 6(1), 1-9.
